Skip to main content

Table 1 Patient characteristics at the time of second-line chemotherapy

From: A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer

  No. of patients (n = 725)
Median age (range), years 56 (22–86)
Male gender 473 (65%)
Prior therapy  
   Surgery 364 (50%)
   Adjuvant chemotherapy ± radiotherapy 145 (20%)
First-line chemotherapy*  
   FP (± leucovorin) or XP 402 (56%)
   ECF or ECX 29 (4%)
   Taxane (paclitaxel or docetaxel) + cisplatin 252 (35%)
   Irinotecan- or oxaliplatin-based 42 (6%)
Response to first-line chemotherapy  
   Responder 143 (20%)
   Non-responder or unknown 582 (80%)
Treatment-free interval, months  
   Median (range) 2 (1–26)
ECOG performance status  
   0–1 586 (81%)
   2 or more 139 (19%)
Involved site(s)  
   Two or more involved sites 283 (39%)
   Ascites 193
   Liver metastasis 139
   Bone marrow involvement (n = 69) 41
Baseline laboratory parameters, median  
   Hemoglobin, g/l 9.8
   Albumin, g/dl 3.4
   Alkaline phosphatase, U/l 86
   Bilirubin, mg/dl 0.5
   Calcium, mg/dl 8.9
  1. *FP, 5-fluorouracil + cisplatin; XP; capecitabine + cisplatin; ECF, epirubicin + cisplatin + 5-fluorouracil; ECX, epirubicin + cisplatin + capecitabine; ECOG, Eastern Cooperative Oncology Group.